Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Drug

HutchMed Completes NDA Submission to US FDA for Frquintinib in Metastatic CRC

Fineline Cube Mar 31, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of a rolling...

Company Deals

Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as ‘APLM’

Fineline Cube Mar 31, 2023

Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the...

Company Drug

Huadong Medicine Wins NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes

Fineline Cube Mar 31, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it...

Company Deals

Ablaze Pharma Charts Path for GPC3-Targeted Polypeptide with RayzeBio Partnership

Fineline Cube Mar 31, 2023

Ablaze Pharma, a Chinese biopharmaceutical company, has announced its development plan for a GPC3-targeted polypeptide...

Company Drug

Fosun Pharmaceutical Gets NMPA Approval for FCN-159 Phase II Study in LCH

Fineline Cube Mar 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...

Company Drug

Shanghai Fosun Pharma Commences Phase III Trial for HER2-Targeted FS-1502

Fineline Cube Mar 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent Chinese pharmaceutical company,...

Company Deals

Kangtai Bio Partners with AstraZeneca and Combiphar to Expand Vaccine Collaboration

Fineline Cube Mar 31, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese vaccine manufacturer, has entered...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Study Published in JCO for R/R ENKTL Treatment

Fineline Cube Mar 31, 2023

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, announced that the Journal of Clinical Oncology...

Medical Device

IceCure Medical Gains NMPA Approval for Cryoablation Technology in China

Fineline Cube Mar 31, 2023

Israel-based IceCure Medical (NASDAQ: ICCM) has announced that it has obtained regulatory approval from China’s...

Company Deals

SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal

Fineline Cube Mar 31, 2023

China-based SciNeuro Pharmaceuticals and Germany’s Secarna Pharmaceuticals GmbH & Co. KG have announced a research...

Company Deals

Beijing’s QL Bio Secures Tens of Millions in Funding for Proteomics Platform Upgrade

Fineline Cube Mar 30, 2023

QL Bio, a Beijing-based proteomics testing company, has reportedly secured tens of millions of renminbi...

Company Drug

ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development

Fineline Cube Mar 30, 2023

China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for...

Policy / Regulatory

Round 8 VBP Tender Results Announced with RMB 21.6 Billion Market

Fineline Cube Mar 30, 2023

The National Allied Procurement Office has issued an initial notification upon the completion of Round...

Company

Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials

Fineline Cube Mar 30, 2023

Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands,...

Company Drug

Janssen to Halt RSV Adult Vaccine Development, Impacting Phase III Trial

Fineline Cube Mar 30, 2023

Johnson & Johnson (J&J; NYSE: JNJ) subsidiary, Janssen, has announced its decision to terminate its...

Company

Luye Pharma Group Reports 15% Revenue Growth in 2022 Financial Results

Fineline Cube Mar 30, 2023

China-based Luye Pharma Group (HKG: 2186) has released its 2022 financial report, recording a total...

Company Drug

Pfizer’s Ritlecitinib Heads for Priority Review in China for Vitiligo Treatment

Fineline Cube Mar 30, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Pfizer’s (NYSE: PFE) ritlecitinib,...

Company Deals

Boston Scientific Partners with Scivita Medtech for Disposable Electronic Cholangioscope

Fineline Cube Mar 30, 2023

Boston Scientific Corporation (NYSE: BSX), a leading figure in the medical device industry, has announced...

Company Drug

Transcenta’s Osemitamab Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Mar 30, 2023

China-based biotechnology company Transcenta Holdings Ltd (HKG: 6628) has announced that its drug TST001 (osemitamab),...

Company Deals

CNBG Partners with China CDC to Strengthen Disease Prevention and Public Health

Fineline Cube Mar 30, 2023

China National Biotec Group Company Limited (CNBG) has announced a significant long-term partnership with the...

Posts pagination

1 … 498 499 500 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.